Cantor Fitzgerald Reiterates Overweight Rating on Celldex Therapeutics (CLDX) - StreetInsider
10 hours ago • Google News
Celldex Therapeutics Inc (CLDX)
US$ 26.22-0.94%
Price Chart
Key Statistics
Market Cap
$ 1.39B
P/E Ratio
0.00
Revenue (TTM)
$ 7.56M
Volume
1.28M
52W High
$ 47.00
52W Low
$ 14.40
Dividend Yield
0.00%
Beta
1.39
Technicals
50-Day MA
19.1268
200-Day MA
26.609
52 Week High
47
52 Week Low
14.4
About CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.
Employees
186
Headquarters
Hampton, NJ
CEO
Mr. Anthony S. Marucci M.B.A.
Latest News
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
2 weeks ago • Google News
Canaccord Genuity Initiates Coverage of Celldex Therapeutics (CLDX) with Buy Recommendation - Nasdaq
4 weeks ago • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg